ClinicalTrials.gg
WithdrawnNCT00713011CARDINALUpdated Nov 16, 2012

Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients

A Phase 3 interventional study of Adalat XL and Tiazac XC in Diabetic Nephropathies and Hypertension, sponsored by Bayer. Withdrawn. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-11-16.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study was stopped by sponsor prior to first patient assignment to groups due to operational reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study consists of a 12 week run-in period when all subjects are stabilized on a single dose of Avalide (300 mg/12.5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends, subjects will be randomly assigned to start the addition of either Adalat XL or Tiazac XC for 18 weeks of treatment. Subjects will have a 1 in 2 chance of receiving the study drug Adalat XL and a 1 in 2 chance of receiving the drug Tiazac XC. An end of treatment visit will be done 18 weeks after start of study drug. The expected duration of the study is 30 weeks. The purpose of this study is to compare the change in proteinuria, through a urine test, while taking study drug until high blood pressure (BP) is reduced to near normal levels in study subjects with diabetic nephropathy and hypertension.

02

Conditions studied

  • Diabetic Nephropathies
  • Hypertension

Keywords

  • Adalat XL
  • Diltiazem
  • Tiazac XC
  • Proteinuria
03

In context

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >/= 18 and \< 80 years old.
  • Diagnosed with hypertension.
  • Diagnosed with diabetes mellitus type 2 for at least 6 mths prior to entry and on stable medication for diabetes for at 1 mth prior to screening.
  • Treated on ARB, ACE inhibitor with or without hydrochlorothiazide and suitable to receive combination therapy with Avalide at 300mg/12.5mg per day or 300mg/25mg per day.
  • Diagnosed with diabetic nephropathy and have proteinuria between 0.8g/day and 5.0g/day at screening and then between 0.8g/day and 3.0g/day at randomization.
  • Medically appropriate to receive Adalat XL or Tiazac XC.

Exclusion criteria

Exclusion Criteria:

  • History of alcohol or substance abuse.
  • Significant CV disorder such as ischemic heart disease, arrhythmias within the last 6 mths, or any history of severe congestive heart failure.
  • Myocarditis or pericarditis within last 30 day of screening.
  • showing evidence of major arrhythmia or conduction disturbances requiring treatment with anti-arrhythmic medication.
  • Females with or males with a partner of child-bearing potential unless willing to use effective during the study and 3 mths after the end of study.
  • Females who are pregnant, lactating or planning pregnancy during the study and for 3 mths after the study end.
  • Known to Adalat XL or Tiazac XC or other calcium channel blockers of the dihydropyridine class.
  • Resting heart rate \<50 or >110 bpm.
  • Presence of secondary or malignant hypertension.
  • DBP >/= 180 and/or SBP >/= 110 mmHg.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Adalat XL

  • Active comparator
    Arm 2

    Drug: Tiazac XC

Interventions

  • Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.

  • DrugTiazac XC

    Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.

06

What researchers measure

Primary outcomes

  1. Change in Proteinuria

    Time frame: Baseline/Randomization to Week 18

Secondary outcomes

  1. Percentage of subjects reaching a BP target of 130/80 mmHg at Week 18

    Time frame: Baseline/Randomization to Week 18

  2. Number and doses of anti-hypertensives used in the 2 treatment arms

    Time frame: Baseline/Randomization to Week 18

  3. Levels of urinary albumin and protein content and estimated glomerular filtration rate (GFR) in the 2 treatment groups

    Time frame: Baseline/Randomization to Week 18

  4. Early BP reduction from randomization achieved with the starting dose in the 2 treatment arms

    Time frame: Baseline/Randomization to Week 1

  5. Adverse Events leading to early withdrawal

    Time frame: Screening to end of study

  6. All Adverse Events especially, edema

    Time frame: Screening to end of study

  7. Change in index of glycemia (HbA1c)

    Time frame: Screening to Week 18

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2008
First posted
Jul 11, 2008
Start
Nov 2008
Primary completionEst.
Mar 2009
CompletionEst.
Mar 2009
Last update
Nov 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00713011
Lead sponsor
Bayer
First posted
Jul 11, 2008
Start date
Nov 2008
Primary completion
Mar 2009 (estimated)
Completion
Mar 2009 (estimated)
Last update
Nov 16, 2012

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion